U.S. markets close in 5 hours 12 minutes
  • S&P 500

    4,126.54
    -13.52 (-0.33%)
     
  • Dow 30

    32,805.88
    -26.66 (-0.08%)
     
  • Nasdaq

    12,501.42
    -143.04 (-1.13%)
     
  • Russell 2000

    1,919.23
    -21.98 (-1.13%)
     
  • Crude Oil

    91.66
    +0.90 (+0.99%)
     
  • Gold

    1,810.50
    +5.30 (+0.29%)
     
  • Silver

    20.47
    -0.15 (-0.72%)
     
  • EUR/USD

    1.0232
    +0.0038 (+0.37%)
     
  • 10-Yr Bond

    2.8010
    +0.0360 (+1.30%)
     
  • GBP/USD

    1.2115
    +0.0034 (+0.28%)
     
  • USD/JPY

    134.9180
    -0.0550 (-0.04%)
     
  • BTC-USD

    23,077.23
    -1,090.28 (-4.51%)
     
  • CMC Crypto 200

    535.54
    -21.81 (-3.91%)
     
  • FTSE 100

    7,494.07
    +11.70 (+0.16%)
     
  • Nikkei 225

    27,999.96
    -249.28 (-0.88%)
     

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So, the natural question for ORIC Pharmaceuticals (NASDAQ:ORIC) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

View our latest analysis for ORIC Pharmaceuticals

When Might ORIC Pharmaceuticals Run Out Of Money?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When ORIC Pharmaceuticals last reported its balance sheet in September 2021, it had zero debt and cash worth US$290m. In the last year, its cash burn was US$62m. Therefore, from September 2021 it had 4.7 years of cash runway. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is ORIC Pharmaceuticals' Cash Burn Changing Over Time?

ORIC Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. During the last twelve months, its cash burn actually ramped up 78%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can ORIC Pharmaceuticals Raise More Cash Easily?

Given its cash burn trajectory, ORIC Pharmaceuticals shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Since it has a market capitalisation of US$389m, ORIC Pharmaceuticals' US$62m in cash burn equates to about 16% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is ORIC Pharmaceuticals' Cash Burn Situation?

It may already be apparent to you that we're relatively comfortable with the way ORIC Pharmaceuticals is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. On another note, ORIC Pharmaceuticals has 4 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.

Of course ORIC Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.